Chris Boerner
About Chris Boerner
Chris Boerner is the Board Chair and Chief Executive Officer at Bristol Myers Squibb, with over two decades of experience in the biopharma industry focusing on cancer, HIV/AIDS, and cardiovascular disease.
Company
Chris Boerner currently serves as the Board Chair and Chief Executive Officer at Bristol Myers Squibb. The company is a prominent global biopharmaceutical company involved in the discovery, development, and delivery of innovative medicines that help patients prevail over serious diseases.
Title
Chris Boerner holds the distinguished positions of Board Chair and Chief Executive Officer at Bristol Myers Squibb. His leadership roles involve overseeing the company's strategic and operational frameworks while ensuring the successful delivery of therapeutic solutions to patients.
Education and Expertise
Chris Boerner has an academic foundation in business and economics, having received a Ph.D. from University of California, Berkeley. He also holds an A.B. in Economics and History from Washington University in St. Louis. His expertise spans over two decades in the biopharma industry, with a focus on conditions such as cancer, HIV/AIDS, and cardiovascular diseases.
Career Background
Chris Boerner has held numerous strategic roles at Bristol Myers Squibb, including Executive Vice President and Chief Operating Officer, Executive Vice President and Chief Commercialization Officer, Head of International Markets, and President and Head of US Commercial. Prior to Bristol Myers Squibb, he was the Executive Vice President of Commercial at Seattle Genetics and held several roles at Genentech, including Director of Marketing and Global Avastin Franchise Team Lead. He also served as a Consultant at Accenture and an Associate at McKinsey & Co.
Achievements
Chris Boerner has led the development of innovative patient engagement strategies and played a key role in expanding Bristol Myers Squibb's pipeline to include new therapeutic areas. He has also advocated for and implemented inclusive workplace policies. His personal motivation to improve patient outcomes is driven by losing a cousin to cancer at a young age. He underscores the importance of combining scientific innovation with a strong workforce to achieve better patient outcomes and emphasizes the need for unprecedented collaboration in the industry.